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OBJECTIVES We sought to determine the role of the 25T/C polymorphism of the platelet glycoprotein
(GP) Iba as a potential risk factor for coronary artery disease (CAD) and adverse events
complicating a coronary catheter intervention.
BACKGROUND The platelet GP Ib-IX-V receptor complex plays a crucial role in arterial thrombus formation.
The 25T/C polymorphism of GP Iba is associated with increased receptor density.
METHODS We genotyped 1,000 patients with angiographically confirmed CAD, as well as 1,000 age-
and gender-matched control subjects, for this polymorphism by polymerase chain reaction/
restriction fragment length polymorphism. Among the patients with CAD, 269 underwent
percutaneous transluminal coronary angioplasty (PTCA), 103 underwent directional coronary
atherectomy and 278 underwent stenting. This intervention group was followed for a 30-day
composite end point of target vessel revascularization, myocardial infarction or death.
RESULTS Carriers of the 25C allele were significantly over-represented in the group of patients
developing acute coronary syndromes (relative risk [RR] 1.43, 95% confidence interval [CI]
1.05 to 1.95, p 5 0.02). The 25C allele furthermore predicted an increased risk for
developing complications after PTCA (RR 3.75, 95% CI 1.15 to 12.27, p 5 0.029).
CONCLUSIONS The 25C allele of the GP Iba Kozak polymorphism may represent a risk factor in clinical
conditions in which thrombosis plays an important role, such as in acute coronary syndromes
and in complications after PTCA. (J Am Coll Cardiol 2001;38:1023–7) © 2001 by the
American College of Cardiology
Thrombosis at the site of atherosclerotic plaque rupture is a
prominent feature in acute coronary syndromes and in vessel
wall injury after coronary interventions. The platelet glyco-
protein (GP) Ib-IX-V receptor complex, comprising four
polypeptides, plays a crucial role in this process by mediating
platelet adhesion by binding von Willebrand factor (vWF)
at the site of the vessel wall lesion (1,2).
We have previously identified a T/C polymorphism in
the Kozak sequence of GP Iba (the vWF-binding subunit
of the complex) at position 25 from the initiator ATG and
demonstrated increased GP Ib-IX-V complex density in
carriers of the 25C allele. A possible explanation for this
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observation could be more efficient messenger ribonucleic
acid translation of the 25C allele, due to closer approxima-
tion of the consensus nucleotide sequence derived by Kozak
(3,4). We hypothesized that a higher GP Iba receptor
density may predispose to thrombotic events.
Very recently, the first published report on the clinical
importance of this polymorphism failed to show a positive
association between this polymorphism and the risk of
coronary artery disease (CAD) in a study of 101 survivors of
acute coronary syndromes (5). However, due to the small
sample size, a possible association might have been missed
(6). We therefore investigated, in a study of 2,000 patients,
the role of the GP Iba 25C allele as a putative risk factor
for CAD, as well as for coronary interventions, including
percutaneous transluminal coronary angioplasty (PTCA),
directional atherectomy (DCA) and stenting.
METHODS
Study group and operational definitions. This study en-
rolled 1,000 consecutive patients with angiographically
proven CAD admitted to the Charite´ University Medical
Center for elective or emergency angiography between
October 1995 and January 1997. An additional 1,000
patients also admitted to this hospital served as the control
group. They were matched by age, gender and time of
hospital admittance. The disease spectrum of the control
group reflects that of a large university hospital that has all
internal and surgical disciplines. Exclusion criteria included
evidence of coronary or peripheral artery disease, or any kind
of vasculitis, according to history, physical examination,
electrocardiography, radiography and echocardiography.
The design of the study has been described in detail
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elsewhere (7). All participants provided written, informed
consent in accordance with a study protocol approved by the
local Ethics Committee.
The definition of CAD was based on angiographic
criteria; the coronary angiograms were reviewed by experi-
enced cardiologists who had no knowledge of the patients’
identity and outcome. Coronary artery disease was defined
as $50% stenosis in a major coronary artery or in a major
branch. The severity of CAD was classified according to the
number of affected arteries (i.e., one-, two- or three-vessel
disease). A diagnosis of myocardial infarction was estab-
lished on the basis of World Health Organization criteria
(8), as well as on angiographic findings. Operational tech-
niques and indications for coronary interventions (e.g.,
PTCA, DCA, stenting) have been described in detail (7).
Adverse events were assessed by the 30-day composite
clinical end point, including the need for target vessel
revascularization (repeat PTCA and coronary artery bypass
graft surgery), myocardial infarction and death. All patients
in the intervention group received aspirin and 10,000 U
heparin before the intervention and, as required, repeated
doses of 2,500 U heparin to maintain an activated clotting
time .250 s. Patients who underwent the stenting proce-
dure also received 500 mg ticlopidine orally after the
procedure and for the following four weeks. Acute coronary
syndromes comprised unstable angina and acute myocardial
infarction. Unstable angina was further stratified according
to the Braunwald classification (9).
Genotyping and biochemical determinations. Genotyp-
ing by polymerase chain reaction/restriction fragment
length polymorphism employed primers 59-TAGTTTTA-
AGTTCTGCAGGCAAGG and 59-AAGGTGTACA-
GGAGGTTCTCACTC (TIB Molbiol, Berlin, Germa-
ny). The 353-base pair (bp) polymerase chain reaction
product was digested by PpuMI (New England Biolabs,
Schwalbach, Germany) into 191-bp and 162-bp fragments
when the 25T allele was present. Fibrinogen, C-reactive
protein (CRP), plasminogen activator inhibitor (PAI-1)
and vWF were determined by standard laboratory methods.
Statistical analysis. Data are presented as the median
values (25th to 75th percentiles); groups were compared by
the Mann-Whitney U test. Odds ratios are given with 95%
confidence intervals (CIs), and p values were calculated by
using the chi-square or Fisher exact test. Logistic regression
analysis, adjusted for atherogenic risk factors and coagula-
tion variables, was applied to test for the impact of GP Iba
genotypes on the risk of CAD.
For patients who underwent coronary interventions, in a
first step, univariate comparison of baseline characteristics,
common risk factors and procedural risk factors was done.
In a second step, we developed a logistic regression model
with the composite end point of adverse events included as
the dependent variable. Independent variables were as
follows: GP Iba–Kozak sequence genotype, gender, diabe-
tes, hypercholesterolemia, hypertension, smoking status,
procedural determinants (unstable angina, acute myocardial
infarction, number of diseased vessels, lesion type [A, B1,
B2, C] and recanalization), as well as indicators of proco-
agulant activation and endothelial function (fibrinogen,
CRP, PAI-1 and vWF). All statistical tests were calculated
using SPSS, version 9.0.
RESULTS
The baseline demographic and clinical characteristics of the
patients are depicted in Table 1. Glycoprotein Iba geno-
typing was successful in 971 patients and 984 control
subjects. The 25C allele frequencies were 18.2% in patients
and 13.8% in control subjects (odds ratio 1.12, 95% CI 0.94
to 1.34, p 5 0.22).
Glycoprotein Iba genotypes and risk of CAD. Genotype
frequencies for patients versus control subjects did not differ
significantly: 71.7% versus 74.7% for the T/T genotype,
26.3% versus 23.1% for the C/T genotype and 2.1% versus
2.2% for the C/C genotype—comparable to values pub-
lished previously (3,5).
Glycoprotein Iba genotypes and acute coronary syn-
dromes. A total of 235 patients with CAD suffered from
acute coronary syndromes (144 with unstable angina and 91
with acute myocardial infarction). Further stratification of
the patients presenting with unstable angina revealed that
39.6% were in Braunwald class I, 34% were in class II and
26.4% were in class III. Logistic regression analysis, ad-
justed for age, gender, diabetes, hypertension, hypercholes-
terolemia, smoking status, vWF, CRP, PAI-1 and fibrino-
gen, revealed that heterozygous and homozygous carriers of
the 25C allele (25C/T 1 25C/C) were at increased risk
for development of acute coronary syndromes, as compared
with those carriers of the wild-type allele (25T/T) (relative
risk [RR] 1.43, 95% CI 1.05 to 1.95, p 5 0.02).
Glycoprotein Iba genotypes and outcome of coronary
interventions. We performed coronary interventions on
673 patients; genotyping was successful in 650 (269 with
PTCA, 103 with DCA and 278 with stenting). Genotype
frequencies did not differ between the entire population and
the intervention group. Table 2 depicts the patients’ char-
acteristics stratified according to the type of coronary
intervention. In the PTCA group, carriers of the T/T
genotype had a significantly lower prevalence of diabetes
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 confidence interval
CRP 5 C-reactive protein
DCA 5 directional coronary atherectomy
GP 5 glycoprotein
PAI-1 5 plasminogen activator inhibitor-1
PTCA 5 percutaneous transluminal coronary angioplasty
RR 5 relative risk
vWF 5 von Willebrand factor
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(p , 0.05) and type A lesions (p , 0.05), but a higher
proportion of type C lesions (p , 0.05), compared with
carriers of the 25C allele. A comparison of the intervention
groups showed that vessel diameters were smaller in the
PTCA group (2.6 mm [range 2.0 to 3.1]) than in the DCA
group (3.3 mm [range 2.0 to 3.9]; p , 0.001) and stent
group (3.1 mm [range 2.0 to 3.5], p , 0.001). In the stent
group, the number of stents per attempted lesion did not
differ significantly between the T/T and T/C 1 C/C
genotypes (1.7 6 0.9 vs. 1.7 6 0.8).
The 30-day composite end point was reached by 42
patients (6.5%) (Table 3), a complication rate comparable to
that of large registries (10). Of these patients, two were
25C/C homozygotes, 15 were 25C/T heterozygotes and
25 were T/T homozygotes. Logistic regression analysis
disclosed that the 25C allele was associated with increased
procedural risk in patients undergoing PTCA (Fig. 1), with
RR 3.75, adjusted for common risk factors, procedural
determinants and indicators of procoagulant activation and
endothelial function (95% CI 1.15 to 12.27, p 5 0.029).















Age (years) 60.4 (54.1, 67.8) 60.7 (57.2, 67.1) 58.5 (51.9, 63.4) 60.6 (54.7, 65.6) 61.1 (55.7, 66.4) 60.3 (55.0, 67.1)
Male 147 (77.4%) 59 (74.7%) 66 (80.5%) 19 (90.5%) 138 (77.1%) 67 (67.7%)
Risk factors
Smoking 98 (51.6%) 38 (48.1%) 40 (48.8%) 11 (52.4%) 85 (47.5%) 39 (39.4%)
Diabetes 34 (17.9%)* 25 (31.6%) 19 (23.2%) 4 (19.0%) 39 (21.8%) 22 (22.2%)
Hypercholesterolemia 101 (53.2%) 38 (48.1%) 48 (58.5%) 7 (33.3%) 104 (58.1%) 58 (58.6%)
Hypertension 101 (53.2%) 50 (63.3%) 35 (42.7%) 12 (57.1%) 96 (53.6%) 52 (52.5%)
History
Acute myocardial infarction 31 (16.3%) 16 (20.3%) 2 (2.4%) 2 (9.5%) 16 (8.9%) 10 (9.9%)
Unstable angina 24 (12.6%) 13 (16.5%) 18 (22.0%) 7 (33.3%) 28 (15.6%) 19 (19.2%)
Recanalization 28 (14.7%) 12 (15.2%) 2 (2.4%) 1 (4.8%) 23 (12.8%) 17 (17.2%)
No. of affected vessels
One 47 (24.7%) 16 (20.3%) 36 (43.9%) 6 (28.6%) 59 (33.0%) 23 (23.2%)
Two 85 (44.7%) 39 (49.4%) 30 (36.6%) 10 (47.6%) 58 (32.4%) 48 (48.5%)
Three 58 (30.6%) 24 (30.3%) 16 (19.5%) 5 (23.8%) 62 (34.6%) 28 (28.3%)
Lesion type
A 45 (23.8%)* 28 (35.0%) 34 (41.4%) 4 (19.0%) 1 (0.6%) 4 (4.0%)
B1 18 (9.5%) 7 (8.7%) 4 (4.8%) 1 (4.8%) 20 (11.1%) 5 (5.1%)
B2 89 (47.1%) 37 (46.3%) 26 (31.8%) 10 (47.6%) 111 (62.0%) 59 (59.6%)
C 37 (19.6%)* 8 (10.0%) 18 (22.0%) 6 (28.6%) 47 (26.3%) 31 (31.3%)
Vessel diameter (mm) 2.6 (2.3, 3.1) 2.6 (2.4, 3.1) 3.3 (2.8, 3.5) 3.6 (2.9, 3.9) 3.1 (2.8, 3.5) 3.1 (2.7, 3.5)
Preprocedural TIMI flow grade ,3 1 (0.5%) 1 (1.3%) 0 0 1 (0.6%) 1 (1.0%)
MLD
Before intervention (mm) 1.0 (0.8, 2.1) 1.0 (0.8, 1.3) 1.1 (0.8, 1.2) 1.0 (0.9, 1.2) 0.5 (0.1, 1.0) 0.4 (0.1, 1.2)
After intervention (mm) 2.0 (1.9, 2.8) 1.9 (1.7, 2.5) 2.5 (1.5, 3.0) 2.7 (2.0, 3.0) 3.0 (2.8, 3.4) 3.1 (2.5, 3.6)
Dissection type $D 3 (1.6%) 3 (3.8%) 1 (1.2%) 0 12 (6.7%) 4 (4.0%)
*p , 0.05 vs. T/C 1 C/C genotype. Data are presented as the median value (25th, 75th percentiles) or number (%) of patients.
DCA 5 directional coronary atherectomy; MLD 5 minimal lumen diameter; PTCA 5 percutaneous transluminal coronary angioplasty; TIMI 5 Thrombolysis In
Myocardial Infarction trial.
Table 1. Demographic and Clinical Data of Patients With CAD (n 5 1,000) and Control




Subjects OR 95% CI p Value
Age (years) 60.6 (55.1, 67.1) 60.5 (54.5, 66.5)
Males 75.9% 75.9% — — —
History
Hypertension 55.2% 35.9% 2.20 1.8–2.6 , 0.001
Hypercholesterolemia 52.7% 30.3% 2.56 2.1–3.1 , 0.001
Diabetes 22.8% 11.4% 2.30 1.8–2.9 , 0.001
Smokers 44.0% 35.2% 1.45 1.2–1.7 , 0.001
Age at manifestation ,40 years 6.8%
Acute myocardial infarction 9.1%
Unstable angina 14.4%
Three-vessel CAD 33.8%
Data are presented as the median value (25th, 75th percentile) or percentage of patients or subjects.
CAD 5 coronary artery disease; CI 5 confidence interval; OR 5 odds ratio.
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However, the 25C allele did not predict an adverse out-
come during DCA and stenting: the RR for C-allele carriers
undergoing DCA was 3.42 (95% CI 0.22 to 53.59, p 5
0.38) and for those undergoing stenting, it was 1.05 (95%
CI 0.31 to 3.59, p 5 0.93).
DISCUSSION
The crucial findings of this study were that carriers of the
25C allele have a greater risk of developing acute coronary
syndromes and complications after PTCA.
We have recently demonstrated that the presence of C
instead of T at position 25 of the GP Iba–Kozak sequence
leads to increased density of the GP Ib-IX-V receptor
complex on platelets (3). We therefore hypothesized that
this mutation could also possess clinical importance.
Thrombus formation at the site of plaque rupture is a
dominant feature of acute coronary syndromes and during
coronary interventions in which the protective endothelial
lining of the arterial wall is disrupted, rendering arteries
susceptible to thrombosis (11). Platelet adhesion, aggrega-
tion and thrombosis may lead to unstable angina and
progress to myocardial infarction (12). The contact of GP
Ib-IX-V complex with vWF is a pivotal step in these
processes (1). Therefore, it was not unexpected that we
observed an increased risk of acute coronary syndromes and
a higher complication rate for PTCA in carriers of the 25C
allele. However, this did not apply for DCA and stenting. A
possible explanation for this discrepancy could be that the
stent group received additional ticlopidine, which inhibits
platelet aggregation and activation of the fibrinogen recep-
tor, GP IIb-IIIa (12). The reason for the lack of an
increased procedural risk in the DCA group might reside in
significantly greater vessel diameters. Moreover, the wide
confidence interval by no means excludes an increased odds
ratio. Therefore, it cannot, of course, be completely ex-
cluded that this result is a chance finding.
Although our working hypothesis was initially centered
on acute thrombotic events, we also investigated whether
the 25C allele predisposes to the development of athero-
sclerosis, particularly in light of our recent findings that GP
Iba also represents a counter-receptor for endothelial
P-selectin and leukocyte Mac-1 (13,14). However, in this
large study, no significant association was evident with
CAD, which is in accordance with the first report on this
Figure 1. Glycoprotein Iba–Kozak sequence genotype predicts increased relative risk for the 30-day composite end point after percutaneous transluminal
coronary angioplasty (PTCA), but not after directional coronary atherectomy (DCA) or stenting. The figure shows relative risks for the GP Iba–Kozak
sequence (C/C 1 C/T) genotype, with 95% confidence intervals (CI) adjusted for common risk factors, procedural determinants and indicators of
procoagulant activation and endothelial function (see text).
Table 3. Glycoprotein Iba Genotype Distribution by 30-Day
Composite End Point and Type of Intervention in Patients
Who Underwent Coronary Interventions
Genotype
p
Value*CT 1 CC TT
PTCA (n 5 269)
No complications 72 183
Composite end point 8 6 0.03
DCA (n 5 103)
No complications 20 77
Composite end point 1 5 1.00
Stenting (n 5 278)
No complication 91 165
Composite end point 8 14 0.94
*Calculated by using the chi-square or Fisher exact test.
Abbreviations as in Table 1.
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issue by Corral et al. (5), who failed to show an association
of the 25C allele with CAD in 101 survivors of acute
coronary syndromes.
Potential limitations. In the interpretation of the present
results, it has to be kept in mind that the study was of
case-control design. Hence, a possible survival bias cannot
be excluded for the group of patients with acute coronary
syndromes. Furthermore, the patients with CAD in our
study must be considered to represent a selected patient
group. Therefore, they may not be representative of all patient
groups, because these patients were referred to a highly
specialized tertiary referral center for a coronary diagnosis and
intervention. Despite the large sample size, due to the number
of patients in certain subgroups, the confidence limits are
broad. Therefore, confirmation of these results in large, inde-
pendent and prospective studies is required.
Clinical implications. It may be possible to reduce the
incidence of early procedure-related complications by iden-
tification of subgroups of patients at higher risk. The 28.4%
prevalence of genotypes containing one or two 25C alleles
among patients with CAD is clinically relevant. Confirma-
tion of our data in further studies would support that
genotyping for GP Iba could prove useful and that inten-
sified antiplatelet therapy should be considered for carriers
of the 25C allele. In addition, GP Iba could also prove to
be an interesting target for antiplatelet therapy.
Conclusions. The Kozak sequence mutation of GP Iba
apparently represents a risk factor in clinical conditions in
which thrombus formation plays an important role, such as in
acute coronary syndromes and adverse events complicating
PTCA. These findings—if supported by further studies—
suggest that genotyping of GP Iba could prove important for
risk stratification and tailoring of antiplatelet therapy.
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